Shih-Hsien Sung
Shih-Hsien Sung is an expert in Cardiology at Taipei Veterans General Hospital (Taiwan). As of October 2026, ScienceLeadR ranks Shih-Hsien Sung in the top 1% of experts in Taiwan for Heart Failure and Hypertension. Shih-Hsien Sung has authored 317 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 3 of them ongoing. SLR score: 1,128 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Endocrinology - Biostatistics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 317
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and or Chronic Kidney Disease (ATTAIN Outcomes) NCT07241390 — kidney diseases, heart diseases, stroke, incidence, heart, cardiovascular diseases, kidney, atherosclerosis, renal insufficiency, renal insufficiency, chronic | Phase 3 | Recruiting | 2025 |
| Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) NCT07157774 — lipoproteins, cardiovascular diseases, atherosclerosis, lipoprotein(a) | Phase 3 | Recruiting | 2025 |
| Study to Evaluate Safety and Efficacy of Mirivadelgat in PH ILD (Windward) NCT06475781 — hypertension, lung, hypertension, pulmonary, safety, oxidoreductases, vascular resistance, signs and symptoms, aldehydes, work, aldehyde dehydrogenase, lung diseases, lung diseases, interstitial | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map